TCT-982 Clinical Characteristics and Outcomes of Transcatheter Tricuspid Valve Replacement (TTVR) Patients Stratified by TRISCEND II Trial Eligibility

Authors

Sahar Razmjou, Henry Ford HealthFollow
Tiberio Frisoli, Henry Ford HealthFollow
Pedro Villablanca, Henry Ford HealthFollow
Pedro Engel Gonzalez, Henry Ford HealthFollow
James Lee, Henry Ford HealthFollow
John Dawdy, Henry Ford HealthFollow
Nathaniel Bowerman, Henry Ford HealthFollow
Brian O'Neill, Henry Ford HealthFollow

Recommended Citation

Razmjou S, Frisoli T, Villablanca P, Engel Gonzalez P, Lee J, Dawdy J, Bowerman N, O'Neill B. TCT-982 Clinical Characteristics and Outcomes of Transcatheter Tricuspid Valve Replacement (TTVR) Patients Stratified by TRISCEND II Trial Eligibility. J Am Coll Cardiol 2025; 86(17):B419-B420.

Document Type

Conference Proceeding

Publication Date

10-28-2025

Publication Title

J Am Coll Cardiol

Abstract

Background: Clinical trials like TRISCEND II use strict criteria that exclude many real-world TTVR patients. Those excluded patients often have worse health status and outcomes. We compared characteristics and results between eligible and non-eligible patients in our TTVR cohort. Methods: We analyzed a single-center cohort of 112 patients who underwent TTVR for symptomatic TR, stratified by TRISCEND II eligibility. Baseline demographics and clinical outcomes were compared between eligible (n=51) and non-eligible (n=61) groups. Results: Eligible patients were older (82.2 ± 8.5 vs. 74.6 ± 8.8 years) and had lower BMI. Sex and NYHA class III/IV distribution were similar (female: 68.6% vs. 63.9%; NYHA III/IV: 74.5% vs. 77.0%). Ineligible patients had lower LVEF (51.6% vs. 58.5%) and more frequent prior heart failure hospitalization (83.6% vs. 58.8%). TR severity was comparable when combining severe and torrential grades (60.7% vs. 64.7%). At 30 days, nearly all patients had TR reduced to moderate or less (95.0% vs. 100%). Ineligible patients were more often NYHA class III/IV (31.0% vs. 11.9%) and had lower KCCQ-OS scores (59.1 ± 24.0 vs. 66.1 ± 22.9). Any bleeding event was more frequent in the ineligible group (39.3% vs. 17.6%), while mortality, stroke, reintervention, and pacemaker rates were low and similar. [Formula presented] Conclusion: TRISCEND II–eligible patients had better baseline cardiac function, fewer prior heart failure hospitalizations, and fewer adverse events after TTVR. These findings highlight the need to consider real-world patient complexity when interpreting outcomes to inform both clinical practice and trial design. Categories: STRUCTURAL: Valvular Disease and Intervention: Tricuspid

Volume

86

Issue

17

First Page

B419

Last Page

B420